Bevacizumab-induced diffusion restriction in patients with glioma: tumor progression or surrogate marker of hypoxia?

J Clin Oncol. 2010 Sep 20;28(27):e477; author reply e478. doi: 10.1200/JCO.2010.29.2029. Epub 2010 Jun 28.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bevacizumab
  • Brain Neoplasms / drug therapy*
  • Brain Neoplasms / pathology
  • Cell Hypoxia
  • Diffusion Magnetic Resonance Imaging*
  • Disease Progression
  • Glioblastoma / drug therapy*
  • Glioblastoma / pathology
  • Humans
  • Neoplasm Recurrence, Local / pathology*
  • Predictive Value of Tests
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Bevacizumab